[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Item 1 of about 1
1. Hammond JW, Hinton RY, Curl LA, Muriel JM, Lovering RM: Use of autologous platelet-rich plasma to treat muscle strain injuries. Am J Sports Med; 2009 Jun;37(6):1135-42
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of autologous platelet-rich plasma to treat muscle strain injuries.
  • BACKGROUND: Standard nonoperative therapy for acute muscle strains usually involves short-term rest, ice, and nonsteroidal anti-inflammatory medications, but there is no clear consensus on how to accelerate recovery.
  • HYPOTHESIS: Local delivery of platelet-rich plasma to injured muscles hastens recovery of function.
  • STUDY DESIGN: Controlled laboratory study.
  • METHODS: In vivo, the tibialis anterior muscles of anesthetized Sprague-Dawley rats were injured by a single (large strain) lengthening contraction or multiple (small strain) lengthening contractions, both of which resulted in a significant injury.
  • The tibialis anterior either was injected with platelet-rich plasma, was injected with platelet-poor plasma as a sham treatment, or received no treatment.
  • RESULTS: Both injury protocols yielded a similar loss of force.
  • The platelet-rich plasma only had a beneficial effect at 1 time point after the single contraction injury protocol.
  • However, platelet-rich plasma had a beneficial effect at 2 time points after the multiple contraction injury protocol and resulted in a faster recovery time to full contractile function.
  • The sham injections had no effect compared with no treatment.
  • CONCLUSION: Local delivery of platelet-rich plasma can shorten recovery time after a muscle strain injury in a small-animal model.
  • Recovery of muscle from the high-repetition protocol has already been shown to require myogenesis, whereas recovery from a single strain does not.
  • This difference in mechanism of recovery may explain why platelet-rich plasma was more effective in the high-repetition protocol, because platelet-rich plasma is rich in growth factors that can stimulate myogenesis.
  • CLINICAL RELEVANCE: Because autologous blood products are safe, platelet-rich plasma may be a useful product in clinical treatment of muscle injuries.

  • MedlinePlus Health Information. consumer health - Sprains and Strains.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Br. 2000 Jan;82(1):131-7 [10697329.001]
  • [Cites] Am J Sports Med. 2005 May;33(5):745-64 [15851777.001]
  • [Cites] Acta Physiol Scand. 2001 May;172(1):63-7 [11437740.001]
  • [Cites] J Bone Joint Surg Am. 2002 May;84-A(5):822-32 [12004029.001]
  • [Cites] Clin Orthop Relat Res. 2002 Oct;(403 Suppl):S81-9 [12394456.001]
  • [Cites] Clin Orthop Relat Res. 2002 Oct;(403 Suppl):S90-9 [12394457.001]
  • [Cites] Inflamm Res. 2003 Oct;52(10):404-7 [14520515.001]
  • [Cites] J Orthop Sports Phys Ther. 2003 Oct;33(10):557-71 [14620785.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 Feb;286(2):C230-8 [14522817.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 Feb;286(2):C355-64 [14561590.001]
  • [Cites] Physiol Rev. 2004 Jan;84(1):209-38 [14715915.001]
  • [Cites] J Appl Physiol (1985). 2004 May;96(5):1619-25 [14672973.001]
  • [Cites] Clin Sports Med. 1983 Mar;2(1):167-82 [6627415.001]
  • [Cites] Cell. 1986 Jul 18;46(2):155-69 [3013421.001]
  • [Cites] Curr Top Dev Biol. 1990;24:95-136 [2165898.001]
  • [Cites] J Appl Physiol (1985). 1992 Mar;72(3):1205-11 [1568975.001]
  • [Cites] J Appl Physiol (1985). 1993 Feb;74(2):520-6 [8458765.001]
  • [Cites] Phys Ther. 1993 Dec;73(12):911-21 [8248299.001]
  • [Cites] J Appl Physiol (1985). 1994 Oct;77(4):1926-34 [7836220.001]
  • [Cites] J Neuroimmunol. 1995 Mar;57(1-2):85-91 [7706442.001]
  • [Cites] J Cell Physiol. 1995 Nov;165(2):307-12 [7593208.001]
  • [Cites] Am J Sports Med. 1996;24(6 Suppl):S2-8 [8947416.001]
  • [Cites] Cytokine Growth Factor Rev. 1996 Oct;7(3):249-58 [8971480.001]
  • [Cites] J Appl Physiol (1985). 1997 Jan;82(1):278-83 [9029227.001]
  • [Cites] Int J Sports Med. 2004 Nov;25(8):582-7 [15532000.001]
  • [Cites] Am J Sports Med. 2005 Jan;33(1):43-51 [15610998.001]
  • [Cites] J Physiol. 2005 Feb 1;562(Pt 3):899-913 [15550464.001]
  • [Cites] Exerc Sport Sci Rev. 2005 Apr;33(2):98-104 [15821431.001]
  • [Cites] J Biomech. 2005 Jul;38(7):1501-7 [15922761.001]
  • [Cites] Cell. 2005 Sep 9;122(5):659-67 [16143100.001]
  • [Cites] Clin Orthop Relat Res. 2005 Oct;439:235-42 [16205165.001]
  • [Cites] J Orthop Res. 2007 Feb;25(2):230-40 [17106885.001]
  • [Cites] J Periodontol. 2007 Apr;78(4):661-9 [17397313.001]
  • [Cites] Arch Phys Med Rehabil. 2007 May;88(5):617-25 [17466731.001]
  • [Cites] J Cell Sci. 2007 Nov 15;120(Pt 22):3999-4008 [17971417.001]
  • [Cites] Br J Sports Med. 2008 May;42(5):314-20 [17984193.001]
  • [Cites] Phys Med Rehabil Clin N Am. 2000 May;11(2):251-66 [10810760.001]
  • (PMID = 19282509.001).
  • [ISSN] 1552-3365
  • [Journal-full-title] The American journal of sports medicine
  • [ISO-abbreviation] Am J Sports Med
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / K01 AR053235; United States / NIAMS NIH HHS / AR / K01AR053235
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS426704; NLM/ PMC3523111
  •  go-up   go-down


Advertisement





Advertisement